-transparent.png){kind=logo}
Sixteen patients with regionally advanced or disseminated nosquamous cell (NSC) head and neck cancer received a monthly combination chemotherapy regimen of cyclophosphamide (C), adriamycin (A), and cis-diamminedichloroplatinum (II) (P), or P, as a single agent administered by either bolus or 24-hour infusion technique. Fifteen patients had received extensive prior surgery and/or radiation therapy. Three patients had prior chemotherapy. A response rate of 50% was achieved (8/16); there were 2 complete regressions and 6 partial regressions. The estimated median time to progression (TTP) for the entire group of 16 patients was 6.0 months and the estimated median survival was 14.0 months. Seven of 8 responders have progressed, with a median TTP of 10.7 months. Virtually all patients experienced alopecia as well as nausea and vomiting, which was more pronounced with the bolus administration of P. Myelosuppression was tolerable; there was no clinically significant renal impairment.
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
January 1981,
Medical and pediatric oncology,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
October 1981,
Gynecologic oncology,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
January 1989,
Auris, nasus, larynx,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
January 1980,
Cancer,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
August 1977,
Cancer treatment reports,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
December 1978,
The Journal of urology,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
April 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
December 1985,
The Southeast Asian journal of tropical medicine and public health,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
July 1982,
Cancer,
E T Creagan, and
J E Woods, and
A J Schutt, and
J R O'Fallon
July 1979,
Cancer,
